Head-to-head · Cost-Efficiency Index
Invigor Medical vs WeightRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalWeightRx
Cost-first shoppers who want the lowest published tirzepatide figure, if you are willing to complete intake before you can read the plan terms.
Visit WeightRxThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 69. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. WeightRx still earns a C — Cost-first shoppers who want the lowest published tirzepatide figure, if you are willing to complete intake before you can read the plan terms.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | WeightRx |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 69/100 |
| Semaglutide / mo | $199/mo | $250/mo (compounded) |
| Tirzepatide / mo | $339/mo | $83/mo (term not published, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $3,000 |
| Tirzepatide / yr (modeled) | $4,068 | $996 |
| Coverage | Not disclosed | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #8 | #122 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
WeightRx
69/100Where the value is
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
The tradeoffs
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.